Abstract
Few data are available on the prevention of fracture in glucocorticoid-treated premenopausal women with autoimmune disorders such as systemic lupus erythematosus. In this setting, Okada et al. compared the effect of coadministration of alfacalcidol alone with that of alfacalcidol combined with alendronate. After 12 months of treatment, lumbar spine bone mineral density increased by 1.7% in the combination group, but decreased by 9.9% in the alfacalcidol-only group (P <0.001). Importantly, although no vertebral fractures were observed in the alendronate group, four patients in the alfacalcidol-only group experienced a vertebral fracture within 12–18 months of treatment. Although these data suggest that alendronate improves bone mineral density, we do not recommend the routine use of bisphosphonates in premenopausal women. Our reasons include the long-term skeletal retention of bisphosphonates, and the possible inhibitory effects on fetal skeletal maturation in pregnant patients. In addition, recent data suggest that premenopausal women who undergo glucocorticoid therapy have a low 10-year absolute risk of fracture.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Curtis JR et al. (2006) Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 55: 420–426
Saag KG et al. (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339: 292–299
Wallach S et al. (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67: 277–285
Reid DM et al. (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15: 1006–1013
Okada Y et al. (2008) Alendronate protects premenopausal women from bone loss and fracture associated with high dose glucocorticoid therapy. J Rheumatol 11: 2249–2254
Lems WF (2007) Bisphosphonates and glucocorticoids: effects on bone quality. Arthritis Rheum 56: 3518–3522
de Nijs RN et al. (2006) Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 355: 675–684
Kanis JA, on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at the primary health-care level [technical report] UK: WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
WF Lems has declared that he has acted at a speaker's bureau for Lilly, Merck Sharp & Dohme (MSD), Proctor Gamble, and Servier.
Rights and permissions
About this article
Cite this article
Lems, W., Geusens, P. Do the benefits of alendronate for premenopausal women on high-dose glucocorticoids outweigh the risks?. Nat Rev Rheumatol 5, 74–75 (2009). https://doi.org/10.1038/ncprheum0991
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0991